FDLI article on Supreme Court KSR decision and pharmaceutical patents
19-1-RISCH
Michael D. Stein Principal Stein IP LLC 1400 Eye Street, NW Suite 300 Washington, DC 20005 (202) 216-9505 [email protected] Nonobviousness.
Nonobviousness II: KSR: Requiem for the Suggestion Test Patent Law – Prof Merges 10.18.2011.
USPTO Guidelines for Determining Obviousness in View of the Supreme Court Decision in KSR International Co. v. Teleflex Inc. TC 1600 Biotech/Chem/Pharma.
Nonobviousness II: Requiem for the Suggestion Test Patent Law – Prof Merges 3.11.08.
